SURPASS-2 was an open-label, 40-week, Phase 3 clinical trial.1879 patients enrolled and received tirzepatide at a dose of 5 mg, 10 mg, or 15 mg, or semaglutide at a dose of 1 mg
It also contributes to keeping desirable levels of hydration in the skin
However, the weight loss journey itselfincluding common side effects such as nausea and fatigue, alongside hormonal and psychological changesmay indirectly influence sexual desire
Your healthcare provider will monitor your weight loss progress, blood sugar levels (if you have diabetes), and overall health to assess the effectiveness of GLP-1 analogues
effective and naturally occurs in the body and s
person is on continuous subcutaneous insulin pump therapy Further information on coping during a period of illness for people with type 1 diabetes is available on the Diabetes UK website (www.diabetes.org.uk)